US FDA approved drugs from 2015–June 2020: a perspective
In the present work, we report compilation and analysis of 245 drugs, including small and
macromolecules approved by the US FDA from 2015 until June 2020. Nearly 29% of the …
macromolecules approved by the US FDA from 2015 until June 2020. Nearly 29% of the …
The multifaceted biology of PCSK9
NG Seidah, A Prat - Endocrine reviews, 2022 - academic.oup.com
This article reviews the discovery of PCSK9, its structure–function characteristics, and its
presently known and proposed novel biological functions. The major critical function of …
presently known and proposed novel biological functions. The major critical function of …
[HTML][HTML] Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors
The viral delivery of base editors has been complicated by their size and by the limited
packaging capacity of adeno-associated viruses (AAVs). Typically, dual-AAV approaches …
packaging capacity of adeno-associated viruses (AAVs). Typically, dual-AAV approaches …
[HTML][HTML] Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
X Bao, Y Liang, H Chang, T Cai, B Feng… - … and Targeted Therapy, 2024 - nature.com
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …
[HTML][HTML] Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting
J Soppert, M Lehrke, N Marx, J Jankowski… - Advanced drug delivery …, 2020 - Elsevier
With cardiovascular disease being the leading cause of morbidity and mortality worldwide,
effective and cost-efficient therapies to reduce cardiovascular risk are highly needed. Lipids …
effective and cost-efficient therapies to reduce cardiovascular risk are highly needed. Lipids …
[HTML][HTML] PCSK9 inhibitors: a new era of lipid lowering therapy
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease
(CVD). The recent American College of Cardiology and American Heart Association …
(CVD). The recent American College of Cardiology and American Heart Association …
PCSK9: a key modulator of cardiovascular health
Since the discovery of proprotein convertase subtilisin kexin 9 (PCSK9) in 2003, this PC has
attracted a lot of attention from the scientific community and pharmaceutical companies …
attracted a lot of attention from the scientific community and pharmaceutical companies …
The biology and therapeutic targeting of the proprotein convertases
NG Seidah, A Prat - Nature reviews Drug discovery, 2012 - nature.com
The mammalian proprotein convertases constitute a family of nine secretory serine
proteases that are related to bacterial subtilisin and yeast kexin. Seven of these (proprotein …
proteases that are related to bacterial subtilisin and yeast kexin. Seven of these (proprotein …
[HTML][HTML] The PCSK9 decade: thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases
G Lambert, B Sjouke, B Choque, JJP Kastelein… - Journal of lipid …, 2012 - ASBMB
PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL
cholesterol (LDL-C) metabolism by virtue of its pivotal role in the degradation of the LDL …
cholesterol (LDL-C) metabolism by virtue of its pivotal role in the degradation of the LDL …
[HTML][HTML] PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis
X Wang, D Wen, Y Chen, L Ma, C You - Cardiovascular diabetology, 2022 - Springer
Abstract Background The Food and Drug Administration has approved Proprotein
Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors for the treatment of dyslipidemia …
Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors for the treatment of dyslipidemia …